Aker BioMarine admitted to trading

The biotech company Aker BioMarine has today been admitted to trading on Merkur Market. Aker BioMarine is the ninth company to be admitted to trading or listing at Oslo Børs so far this year.

Aker BioMarine recently raised NOK 2.15 billion in new equity through a share issue.

“There has been a fantastic level of interest among investors, and the issue was fully subscribed within hours of publishing the stock exchange announcement on Friday 19 June. Our admission to trading on Merkur Market represents an important milestone for Aker BioMarine and we are looking forward to listing the company on Oslo Børs’ main market in the first quarter of 2021”, comments Katrine Klaveness, CFO at Aker BioMarine.

Supporting the company’s growth plans
The funds raised through the issue have strengthened the company’s equity and will support its growth plans. Aker BioMarine develops krill-based products for the consumer and animal feed markets.

“Aker BioMarine has grown from a start-up company focused on capturing and producing krill into an integrated ingredients and branded goods company with control over the entire value chain. In recent years we have made a number of significant investments and carried out extensive research and development, and this continues to open up new opportunities for us in new markets”, explains Matts Johansen, CEO of Aker BioMarine.

An unusually high level of activity in the primary market
Companies have flocked to Oslo Børs in recent months. Since the onset of the pandemic in March, six new companies have been admitted to listing or trading, and Aker BioMarine is the ninth company to be admitted to listing or trading since the start of the year.

“It is not often that we see so much activity in the primary market. Oslo Børs is committed to being a source of capital for business and industry, and in recent months it has been a plentiful source of capital - both for new companies and for companies already admitted to listing or trading that need capital in order to grow and adapt”, comments Øivind Amundsen, the President and CEO of Oslo Børs.

Including Aker BioMarine’s issue, NOK 21.2 billion has been raised through share issues so far this year, with the majority raised during the past few months. Since March, NOK 16.6 billion of new equity capital has been raised.

Aker BioMarine

Foto: Trygve Indrelid/NTB 

About Aker BioMarine
Aker BioMarine is a biotech innovator and Antarctic krill-harvesting company, developing krill-based ingredients for nutraceutical, aquaculture, and animal feed applications. The company’s fully transparent value chain stretches from sustainable krill harvesting in pristine Antarctic waters through its Montevideo logistics hub and Houston production plant, all the way to customers around the world. The company is dedicated to improving human and planetary health.
https://www.akerbiomarine.com/

About Oslo Børs
Oslo Børs is the central marketplace for listing and trading of financial instruments in the Norwegian market. For over 200 years, we have provided companies with access to capital to finance growth, innovation and new jobs.
Our internationally recognized position as a world leader in the energy, seafood and shipping segments attracts listed companies from all over the world.
Oslo Børs is part of Euronext, the largest stock exchange group in Europe with around 1,500 companies listed on markets in six countries.
www.oslobors.no
www.euronext.com

Contact us

Geir Harald Aase